About: Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen
Creator	Lu, Guangwen Deng, Yao Tan, Wenjie Wang, Wen Lan, Jiaming Gao, George Chen, Hong Guo, Xiaojuan Lu, Zhuozhuang
source	Medline; PMC
abstract	The development of an effective vaccine is critical for prevention of a Middle East respiratory syndrome coronavirus (MERS-CoV) pandemic. Some studies have indicated the receptor-binding domain (RBD) protein of MERS-CoV spike (S) is a good candidate antigen for a MERS-CoV subunit vaccine. However, highly purified proteins are typically not inherently immunogenic. We hypothesised that humoral and cell-mediated immunity would be improved with a modification of the vaccination regimen. Therefore, the immunogenicity of a novel MERS-CoV RBD-based subunit vaccine was tested in mice using different adjuvant formulations and delivery routes. Different vaccination regimens were compared in BALB/c mice immunized 3 times intramuscularly (i.m.) with a vaccine containing 10 µg of recombinant MERS-CoV RBD in combination with either aluminium hydroxide (alum) alone, alum and polyriboinosinic acid (poly I:C) or alum and cysteine-phosphate-guanine (CpG) oligodeoxynucleotides (ODN). The immune responses of mice vaccinated with RBD, incomplete Freund’s adjuvant (IFA) and CpG ODN by a subcutaneous (s.c.) route were also investigated. We evaluated the induction of RBD-specific humoral immunity (total IgG and neutralizing antibodies) and cellular immunity (ELISpot assay for IFN-γ spot-forming cells and splenocyte cytokine production). Our findings indicated that the combination of alum and CpG ODN optimized the development of RBD-specific humoral and cellular immunity following subunit vaccination. Interestingly, robust RBD-specific antibody and T-cell responses were induced in mice immunized with the rRBD protein in combination with IFA and CpG ODN, but low level of neutralizing antibodies were elicited. Our data suggest that murine immunity following subunit vaccination can be tailored using adjuvant combinations and delivery routes. The vaccination regimen used in this study is promising and could improve the protection offered by the MERS-CoV subunit vaccine by eliciting effective humoral and cellular immune responses.
has issue date	2014-11-18(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0112602
bibo:pmid	25405618
has license	cc-by
sha1sum (hex)	c9e24b269c1f1772454a1e93cc72c85251aeda6b
schema:url	https://doi.org/10.1371/journal.pone.0112602
resource representing a document's title	Tailoring Subunit Vaccine Immunity with Adjuvant Combinations and Delivery Routes Using the Middle East Respiratory Coronavirus (MERS-CoV) Receptor-Binding Domain as an Antigen
has PubMed Central identifier	PMC4236105
has PubMed identifier	25405618
schema:publication	PLoS One
resource representing a document's body	covid:c9e24b269c1f1772454a1e93cc72c85251aeda6b#body_text
is schema:about of	named entity 'T-cell' named entity 'splenocyte' named entity 'optimized' named entity 'neutralizing antibodies' named entity 'pandemic' named entity 'adjuvant' named entity 'mice' named entity 'vaccination' named entity 'alum' named entity 'routes' named entity 'development' named entity 'The' named entity 'IgG' named entity 'Vaccine' named entity 'Respiratory' covid:arg/c9e24b269c1f1772454a1e93cc72c85251aeda6b named entity 'CpG' named entity 'combinations' named entity 'vaccination' named entity 'recombinant' named entity 'studies' named entity 'neutralizing antibodies' named entity 'humoral' named entity 'routes' named entity 'RBD' named entity 'protein' named entity 'CpG' named entity 'subunit' named entity 'MERS-CoV' named entity 'antibody' named entity 'delivery routes' named entity 'subunit vaccine' named entity 'humoral' named entity 'cell-mediated immunity' named entity 'cysteine' named entity 'recombinant' named entity 'murine' named entity 'alum' named entity 'immunogenicity' named entity 'MERS-CoV' named entity 'RBD' named entity 'BALB/c' named entity 'RBD' named entity 'alum' named entity 'protein' named entity 'vaccination' named entity 'subcutaneous' named entity 'aluminium hydroxide' named entity 'ELISpot' named entity 'mice' named entity 'immune responses' named entity 'Antigen' named entity 'Middle East' named entity 'domain' named entity 'TMB' named entity 'RBD' named entity 'antibody' named entity 'immune response' named entity 'vaccination' named entity 'RBD' named entity 'adjuvants' named entity 'neutralizing antibodies' named entity 'MERS-CoV' named entity 'streptavidin' named entity 'MERS-CoV' named entity 'neutralizing antibodies' named entity 'IgG2b' named entity 'adjuvant' named entity 'IgG' named entity 'MERS-CoV' named entity 'cellular immune response' named entity 'lungs' named entity 'RBD'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software